What is the controversy over the spinal muscular atrophy drug in Keralam? Explained
Reported by The Hindu Sci-Tech, not nibnow. We are not the publisher of this story, only the source is.
Parents of children with spinal muscular atrophy are questioning the switch from a branded to a generic drug, fearing it may affect treatment, and the issue has drawn political attention in Kerala.
After the government switched the drug in its SMA programme from branded to generic, parents of children living with SMA have been asking for a switch back to the branded version; meanwhile the label on a drug bottle has sparked concerns, and political parties have now latched on to the issue
Spinal muscular atrophy is a rare genetic disease that requires specific medication, and governments sometimes replace branded medicines with cheaper generics to reduce healthcare costs.
- •Potential reversal of the generic switch by the Kerala government
- •Statements or actions by political parties regarding the drug issue
- •Any legal or regulatory challenges concerning the drug labeling